GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (MEX:FGEN) » Definitions » Cyclically Adjusted Revenue per Share

FibroGen (MEX:FGEN) Cyclically Adjusted Revenue per Share : MXN50.47 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is FibroGen Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

FibroGen's adjusted revenue per share for the three months ended in Mar. 2025 was MXN0.555. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN50.47 for the trailing ten years ended in Mar. 2025.

During the past 12 months, FibroGen's average Cyclically Adjusted Revenue Growth Rate was -11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-25), FibroGen's current stock price is MXN5.92. FibroGen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN50.47. FibroGen's Cyclically Adjusted PS Ratio of today is 0.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of FibroGen was 7.01. The lowest was 0.12. And the median was 0.28.


FibroGen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for FibroGen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen Cyclically Adjusted Revenue per Share Chart

FibroGen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 45.43 53.49

FibroGen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.05 61.89 47.51 53.49 50.47

Competitive Comparison of FibroGen's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, FibroGen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where FibroGen's Cyclically Adjusted PS Ratio falls into.


;
;

FibroGen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, FibroGen's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.555/134.9266*134.9266
=0.555

Current CPI (Mar. 2025) = 134.9266.

FibroGen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 27.511 100.684 36.868
201509 5.433 100.392 7.302
201512 6.826 99.792 9.229
201603 7.829 100.470 10.514
201606 23.921 101.688 31.740
201609 9.260 101.861 12.266
201612 11.562 101.863 15.315
201703 8.657 102.862 11.356
201706 7.857 103.349 10.258
201709 9.697 104.136 12.564
201712 7.339 104.011 9.520
201803 7.000 105.290 8.970
201806 10.312 106.317 13.087
201809 6.425 106.507 8.139
201812 24.929 105.998 31.733
201903 5.401 107.251 6.795
201906 40.116 108.070 50.086
201909 7.527 108.329 9.375
201912 1.721 108.420 2.142
202003 6.486 108.902 8.036
202006 11.067 108.767 13.729
202009 10.384 109.815 12.759
202012 14.181 109.897 17.411
202103 8.567 111.754 10.343
202106 5.256 114.631 6.187
202109 34.556 115.734 40.286
202112 3.658 117.630 4.196
202203 13.017 121.301 14.479
202206 6.415 125.017 6.924
202209 3.375 125.227 3.636
202212 7.125 125.222 7.677
202303 6.883 127.348 7.293
202306 7.775 128.729 8.149
202309 7.116 129.860 7.394
202312 -12.718 129.419 -13.259
202403 4.253 131.776 4.355
202406 9.293 132.554 9.459
202409 9.076 133.029 9.205
202412 -25.493 133.157 -25.832
202503 0.555 134.927 0.555

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


FibroGen  (MEX:FGEN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

FibroGen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.92/50.47
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of FibroGen was 7.01. The lowest was 0.12. And the median was 0.28.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


FibroGen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of FibroGen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (MEX:FGEN) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.